SPW 5186

Drug Profile

SPW 5186

Alternative Names: SP/W 5186; SPM 5186

Latest Information Update: 30 Apr 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Schwarz Pharma
  • Developer GlaxoSmithKline; Schwarz Pharma
  • Class Organic nitrates
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris

Most Recent Events

  • 30 Apr 2001 Discontinued-II for Angina pectoris in Germany (PO)
  • 30 Apr 2001 Discontinued-II for Angina pectoris in United Kingdom (PO)
  • 30 Apr 2001 Discontinued-Preclinical for Angina pectoris in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top